How we treat systemic light-chain amyloidosis
Chakra P Chaulagain1, Raymond L Comenzo2
1Taussig Cancer Institute of Cleveland Clinic, Weston, Florida.
Clinical Advances in Hematology & Oncology : H&O
|September 10, 2015
Summary
Systemic light-chain amyloidosis causes organ damage from abnormal proteins. Despite current treatments, new therapies are needed to reverse this damage, alongside supportive care and considering transplantation for advanced cases.
Area of Science:
- Hematology
- Oncology
- Nephrology
Background:
- Systemic light-chain (AL) amyloidosis is a multisystem disease.
- Caused by monoclonal free light chains from plasma cell clones.
- Leads to significant organ toxicity and damage.
Purpose of the Study:
- To review current treatment strategies for AL amyloidosis.
- To highlight the need for novel therapies to reverse organ damage.
- To emphasize the importance of supportive care and organ transplantation in advanced disease.
Main Methods:
- Review of existing literature on AL amyloidosis treatments.
- Analysis of current therapeutic approaches including chemotherapy and stem cell transplantation.
- Discussion of supportive care and organ transplantation roles.
Main Results:
- Current treatments target plasma cell clones to reduce light chain production.
- Existing therapies include corticosteroids, chemotherapy, stem cell transplantation, proteasome inhibitors, and immunomodulatory drugs.
- AL amyloidosis remains challenging, often incurable, with a need for organ damage reversal.
Conclusions:
- Novel treatment approaches are urgently required to reverse organ damage in AL amyloidosis.
- Best supportive care is crucial for patients with advanced organ dysfunction.
- Organ transplantation is a viable option in selected clinical situations.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Related Concept Videos
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
01:20Myasthenia Gravis: Overview and Treatment
3.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.4K
01:29Cardiomyopathy V: Interprofessional Care
647
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
647
01:26Atherosclerosis III: Management
589
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
589
01:24Nephrotic Syndrome III : Nursing Management
448
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
448
01:14Myocarditis III: Medical Management
324
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
324